期刊文献+

米非司酮调控乳腺癌细胞凋亡的研究

Effect of mifepristone on the apoptosis of human breast cancer cell line T47D in vitro
下载PDF
导出
摘要 目的:研究米非司酮促进乳腺癌T47D细胞凋亡的作用。方法:根据米非司酮的处理浓度分为0.25μmol/L组、2.5μmol/L组、25μmol/L组和50μmol/L组,各组分别加入相应浓度米非司酮处理人乳腺癌T47D细胞2d后,采用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记测定法检测细胞凋亡,在荧光显微镜下观察绿色荧光细胞数量和荧光强度,采用膜联蛋白V-异硫氰酸荧光素/碘化吡啶法在流式细胞仪上检测凋亡细胞百分率。结果:25μmol/L组和50μmol/L组与对照组比较,阳性绿色荧光细胞的数量更多,荧光强度更强;25μmol/L组和50μmol/L组的凋亡细胞百分比(分别为16.1±3.5%和17.2±3.8%)高于对照组(5.1±2.3%),差异有统计学意义(分别为P=0.010和P=0.009);0.25μmol/L组和2.5μmol/L组的凋亡细胞百分比与对照组比较差异无统计学意义(分别为P=0.818和P=0.884)。结论:米非司酮能够促进乳腺癌T47D细胞的凋亡,且随着米非司酮剂量的升高,凋亡细胞数量增加。 Objective: To investigate the promoting effect of mifepristone on the apoptosis of human breast cancer cells T47D in vitro. Methods: T47D cells were treated by different concentrations (0.25, 2.5, 25 and 50μmol/L) of mife- pristone. Then the apoptosis of these cells was examined by TUNEL assay under the microscope on day 2. The apopto- sis was also examined by Annexin V--FITC assay. Results: Compared with the control group, the number and intensi- ties of the TUNEL--positive cells in 25μmol/L group and 50μmol/L group were significantly higher and stronger. The apoptosis rates of 25μmol/L group (16.1±3.5%, P=0.010) and 50μmol/L group (17.2±3.8%, P=0.009) were sig- nificantly higher than that of the control group (5.1 ± 2.3 % ). There were no significant differences between the control group and 0.25μmol/L group (P=0.818) as well as 2.5μmol/L group (P =0.884). Conclusion: Mifepristone can in- duce the apoptosis of T47D cells in a dose--dependent manner.
出处 《中国计划生育学杂志》 2014年第5期300-303,共4页 Chinese Journal of Family Planning
基金 中央级公益性科研院所基本科研专项基金(2010GJSSJKA04) 北京市自然科学基金资助项目(7132160)
关键词 米非司酮 乳腺癌 T47D 细胞凋亡 流式检测 Mifepristone Breast cancer cell T47D cell Apoptosis Flow eytometry
  • 相关文献

参考文献12

  • 1Gavrieli Y,Sherman Y,Ben-Sasson SA.Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation[J].J Cell Biol,1992,119(3):493-501.
  • 2Periyasamy-Thandavan S,Takhar S,Singer A,et al.Insulin-like growth factor 1 attenuates antiestrogen-and antiprogestin-in duced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim[J].Breast Cancer Res,2012,14(2):R52.
  • 3Fauvet R,Dufournet Etienne C.Effects of progesterone and anti progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line,OVCAR-3[J].Oncol Rep,2006,15(4):743-748.
  • 4Tieszen CR,Goyeneche AA,Brandhagen BN,et al.Antipro gestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression[J].BMC Cancer,2011,11:207.
  • 5Goyeneche AA,Seidel EE,Telleria CM.Growth inhibition induced by antiprogestins RU-38486,ORG-31710,and CDB-2914in ovarian cancer cells involves inhibition of cyclin dependent kinase2[J].Invest NewDrugs,2012,30(3):967-980.
  • 6Navo MA,Smith JA,Gaikwad A,et al.In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines[J].Cancer Chemother Pharmacol,2008,62(3):483-489.
  • 7Dai L,Liu Y,Liu J,et al.A novel cyclinE/cyclinA-CDK inhibi tor targets p27(Kip1) degradation,cell cycle progression and cell survival:implications in cancer therapy[J].Cancer Lett,2013,333(1):103-112.
  • 8Narvekar N,Critchley HO,Cheng L,et al.Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decreasein stromal vascular endothelial growth factor[J].Hum Reprod,2006,21(9):2312-2318.
  • 9W(a)nggren K,Lalitkumar PG,Hambiliki F,et al.Leukaemia inhibitory factor receptor and gp130 in the human Fallopian tube and endometrium before and after mifepristone treatment and in the human preimplantation embryo[J].Mol Hum Reprod,2007,13(6):391-397.
  • 10Freeburg EM,Goyeneche AA,Seidel EE,et al.Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity[J].Cancer Cell Int,2009,9:4.

二级参考文献23

  • 1Kim JJ, Kurita T, Bulun SE. Progesterone Action in endometrial cancer, endometriosts, uterine fibroids, and breast cancer[J]. Endocr Rev,2013,34: 130-162.
  • 2Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486[J]. J Clin Endocrinol Metab, 1993,76 : 513-517.
  • 3Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry[J]. Expert Opin Pharmacother, 2008,9 : 2487- 2496.
  • 4Benad P, Rauner M, Rachner TD, et al. The anti progestin RU 486 inhibits viability of MCF-7 breast cancer cells by suppressing WNTI[J]. Cancer Lett,20l 1 ,312: 101-108.
  • 5Engman M, Skoog L, Soderqvist G, et al. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology[J].Hum Reprod,2008,23:2072 -2079.
  • 6Poole AJ,Li Y, Kim Y, et al. Prevention of Brcal mediated mammary tumorigenesis in mice by a progesterone antagonist [J]. Science, 2006,314 : 1467-1470.
  • 7Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo[J]. Clin Cancer Res,2007,13.-3370 3379.
  • 8Rackow BW, Arici A. Options for medical treatment of myomas[J]. Obstet Gynecol Clin North Am, 2006, 33: 97-113.
  • 9Ramondetta I.M,Johnson AJ,Sun CC,et al. Phase 2 trial of mifepristone(RU-486)in advanced or recurrent endometrioid adenocarcinorna or low grade endometrial stromal sarcoma [J]. Cancer, 2009,115 : 1867-1874.
  • 10Rocereto TF,Saul HM, Aikins JA Jr, et al. Phase Ⅱ study of mifepristone (RU486) in refractory ovarian cancer[J]. Gynecol Oncol, 2000,77 : 429-432.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部